# A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

> **NCT07465289** · PHASE3 · NOT_YET_RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 100 (estimated)

## Conditions studied

- Ocular Myasthenia Gravis

## Interventions

- **DRUG:** Rozanolixizumab

## Key facts

- **NCT ID:** NCT07465289
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2031-01-23
- **Final completion:** 2031-01-23
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465289, "A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07465289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*